Literature DB >> 21366812

Relationship between MTNR1B (melatonin receptor 1B gene) polymorphism rs10830963 and glucose levels in overweight children and adolescents.

Thomas Reinehr1, André Scherag, Hai-Jun Wang, Christian L Roth, Michaela Kleber, Susann Scherag, Tanja Boes, Carla Vogel, Johannes Hebebrand, Anke Hinney.   

Abstract

AIMS: The G-allele of the single nucleotide polymorphism (SNP) rs10830963 in MTNR1B (melatonin receptor 1B gene) is associated with type 2 diabetes mellitus and glucose levels in adults. The aim of this study was to analyze whether there is an allele-dosage effect on glucose metabolism in overweight children and to explore if changes in glucose metabolism in a lifestyle intervention do also depend on genotype.
METHODS: We genotyped rs10830963 in 1118 overweight children and adolescents [mean age 10.7 yr, mean body mass index (BMI) 27.8 kg/m2]; 340 of these individuals completed a 1-yr lifestyle intervention (mean age 10.7 yr, mean BMI 27.9 kg/m2). The degree of overweight [BMI-SDS (standard deviation score)], fasting insulin, glucose, homeostasis model assessment for insulin resistance (HOMA-IR), and quantitative insulin sensitivity check index (QUICKI) were measured before and after intervention.
RESULTS: We showed a significant relationship between rs10830963 and basal glucose levels [β:1.101, 95% confidence interval (CI) 0.316-1.886 mg/dL per risk allele; p = 0.006] by linear regression adjusted for age, age(2), and sex. There was no effect of the allele on insulin or indices of insulin resistance or sensitivity. After the 1-yr lifestyle intervention, we observed a significant reduction of BMI-SDS as well as an improvement of HOMA-IR and QUICKI, but no evidence for an association between rs10830963 genotype and changes of glucose levels.
CONCLUSIONS: The G-allele of rs10830693 in the MTNR1B gene was significantly related to glucose levels, while an impact of this genetic variant on the changes in glucose metabolism in children participating in a lifestyle intervention was not observable.
© 2011 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21366812     DOI: 10.1111/j.1399-5448.2010.00738.x

Source DB:  PubMed          Journal:  Pediatr Diabetes        ISSN: 1399-543X            Impact factor:   4.866


  6 in total

1.  Melatonin in aging and disease -multiple consequences of reduced secretion, options and limits of treatment.

Authors:  Rüdiger Hardeland
Journal:  Aging Dis       Date:  2011-02-10       Impact factor: 6.745

Review 2.  Melatonin in type 2 diabetes mellitus and obesity.

Authors:  Angeliki Karamitri; Ralf Jockers
Journal:  Nat Rev Endocrinol       Date:  2019-02       Impact factor: 43.330

Review 3.  Membrane Melatonin Receptors Activated Cell Signaling in Physiology and Disease.

Authors:  Georgi Nikolaev; Ralitsa Robeva; Rossitza Konakchieva
Journal:  Int J Mol Sci       Date:  2021-12-31       Impact factor: 5.923

4.  Interactions between nocturnal melatonin secretion, metabolism, and sleeping behavior in adolescents with obesity.

Authors:  Johanna Overberg; Laura Kalveram; Theresa Keller; Heiko Krude; Peter Kühnen; Susanna Wiegand
Journal:  Int J Obes (Lond)       Date:  2022-02-09       Impact factor: 5.551

5.  Novel genetic loci identified for the pathophysiology of childhood obesity in the Hispanic population.

Authors:  Anthony G Comuzzie; Shelley A Cole; Sandra L Laston; V Saroja Voruganti; Karin Haack; Richard A Gibbs; Nancy F Butte
Journal:  PLoS One       Date:  2012-12-14       Impact factor: 3.240

6.  Association of melatonin receptor 1 B gene (rs10830963 and rs9192552) polymorphısm with adolescent obesity and related comorbidities in Turkey.

Authors:  Nilgün Çöl; Muradiye Nacak; Mustafa Araz
Journal:  J Int Med Res       Date:  2018-05-04       Impact factor: 1.671

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.